A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Biologic Effect of VG2025 in Patients with Solid Tumors

NCT05477849 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

30

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Malignant Solid Tumor

Interventions

DRUG: Recombinant Human IL12/15 Dual-Regulated Oncolytic HSV-1 Injection

Sponsor

Shanghai Virogin Biotech Co., Ltd.